Atopic dermatitis is increasing in prevalence and currently affects 15-30% of children in urban areas. Immune dysregulation and an impaired epidermal barrier are important factors in the ...
Credit: Arcutis Biotherapeutics, Inc./GlobeNewswire. Arcutis Biotherapeutics‘ subsidiary, Arcutis Canada, has received Health Canada’s approval for ZORYVE (roflumilast) topical foam 0.3%, to treat ...